Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

391830

	registered interest
	date	21/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prosthetics
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will request that NHS England publish a timeline for the re-publication of a commissioning policy on (a) microprocessor knees, (b) multi-articulating prosthetic hands and (c) custom made silicon covers.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	8279
	answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>NHS England has advised that it has commissioned an independent evidence review in relation to microprocessor knees, multi-articulating prosthetic hands and custom made silicon covers which is expected to be complete by September 2015. A more detailed understanding of next steps including potential timelines will be possible once the evidence review has been considered by NHS England.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2015 11:14:54 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

391816

	registered interest
	date	21/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Medical Treatments: Innovation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will request that NHS England clarify the mechanisms available for manufacturers of medical technologies to appeal against a negative specialised service commissioning policy decision.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	8282
	answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>There is no formal appeals process. All stakeholders - including manufacturers, patients and patient groups - are invited to submit their views on proposed commissioning polices via a process of public consultation, the outcome of which is considered by the Clinical Priorities Advisory Group when it meets to form recommendations to NHS England on whether a proposed policy should be commissioned.</p><p> </p><p><strong> </strong></p><p> </p><p>Decisions that are made can be reconsidered at a later date when new evidence is presented.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2015 11:00:41 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

391818

	registered interest
	date	21/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will request that NHS England publish the criteria for approving a specialised service commissioning policy.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	8283
	answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>The criteria used for approving specialised service commissioning policy, entitled <em>NHS England’s response to a public consultation &quot;Investing in specialised services&quot;</em> can be found on the NHS England website:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/nhse-respns-publictn-17-06-15.pdf" target="_blank">http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/nhse-respns-publictn-17-06-15.pdf</a></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2015 11:22:21 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

391839

	registered interest
	date	21/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many (a) new cancer medicines and (b) new indications of existing cancer medicines are expected to be licensed between July 2015 and 31 March 2016.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	8162
	answer	answer is ministerial correction date of answer 07/09/2015 answer text <p>There are currently 11 applications for new cancer medicines and 15 applications for new indications for existing cancer medicines under review by the Medicines and Healthcare products Regulatory Agency (MHRA) as part of European Centralised Procedures submitted to the European Medicines Agency (EMA). There is one further application for a new indication for an existing cancer medicine under review by MHRA in an application submitted in the United Kingdom as part of a Mutual Recognition Procedure.</p><p> </p><p> </p><p> </p><p>Under European Centralised Procedures, it takes up to 210 days for an opinion on licensing for new applications and 120 days for an opinion on variation applications for new indications to be given by the scientific committee of the EMA, the Committee for Human Medicinal Products (CHMP), excluding time taken by the Company to provide further information or data to support any questions which may arise during the assessment process. If the assessment concludes that the quality, safety and efficacy are satisfactory and a positive opinion is given by the CHMP, the European Commission will then consider the opinion and decide upon granting or varying a marketing authorisation, valid across the European Community. For a national variation procedure, the same timeline of 120 days, excluding time taken by the Company to provide further information, applies.</p><p> </p><p> </p><p> </p><p>At this time, the MHRA, the UK Government body responsible for medicines regulation in the UK, is unable to provide more precise detail on the timeline for completion of the review of the applications currently with the EMA and MHRA, and it is not possible to predict with certainty what will be licensed between July 2015 and 31 March 2016, nor can any information be provided on applications not yet submitted but which may be approved before 31 March 2016.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/09/2015 12:35:00 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

391843

	registered interest
	date	21/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether he plans for a new system for the reimbursement of cancer drugs to be in place by April 2016 when the current Cancer Drugs Fund is proposed to end.
	tabling member constituency	Denton and Reddish
	tabling member printed	Andrew Gwynne
	uin	8164
	answer	answer is ministerial correction date of answer 07/09/2015 answer text <p>NHS England has advised that the Cancer Drugs Fund in its current form is due to operate until 1 April 2016. We understand that NHS England and the National Institute for Health and Care Excellence will shortly be consulting jointly on a proposed new system for commissioning cancer drugs.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/09/2015 15:14:37 answering member 4020 label Biography information for George Freeman
	tabling member	1506 label Biography information for Andrew Gwynne

391815

	registered interest
	date	21/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Streptococcus: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to the recent Royal College of Obstetricians and Gynaecologists audit which reported that more than half of all obstetric units tested some or all pregnant women for group B Streptococci using tests not designed specifically to detect group B Streptococci, what the Government's plans are to introduce Public Health England's recently updated UK Standards for Microbiology Investigations, B58 Detection of carriage of Group B Streptococci; and what the planned timescale is for that introduction.
	tabling member constituency	Middlesbrough
	tabling member printed	Andy McDonald
	uin	8291
	answer	answer is ministerial correction date of answer 08/09/2015 answer text <p>Public Health England has advised the Department that the UK Standard for Microbiology Investigation (SMI) B58 <em>Detection of Carriage of Group B Streptococc</em>i was published in June 2015 and is available at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/438182/B_58i3.pdf" target="_blank">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/438182/B_58i3.pdf</a></p><p> </p><p> </p><p> </p><p>SMIs are intended as a general resource for practising professionals operating in the field of laboratory medicine and infection specialties in the United Kingdom.</p><p> </p><p> </p><p> </p><p>They represent neither minimum standards of practice nor the highest level of complex laboratory investigation possible, and are not mandatory. Laboratories can download and adapt the method into a Standard Operating Procedure (SOP) based on local policies. SMIs help laboratories to meet accreditation requirements by promoting high quality practices which are auditable. UK microbiology laboratories that do not use SMIs should be able to demonstrate at least equivalence in their testing methodologies to the relevant accreditation body.</p><p> </p><p> </p><p> </p><p>SMI B58 describes the examination of specimens to detect carriage of Group B streptococci (GBS). SMI B58 states that it does not seek to contradict clinical guidelines from the Royal College of Obstetricians and Gynaecologists or the National Institute for Health and Care Excellence, or those of the UK National Screening Committee 2012 which did not recommend antenatal screening for GBS.</p><p> </p> answering member constituency Ipswich answering member printed Ben Gummer question first answered 08/09/2015 15:49:19 answering member 3988 label Biography information for Ben Gummer
	tabling member	4269 label Biography information for Andy McDonald

391821

	registered interest
	date	21/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Streptococcus
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what guidance his Department has issued (a) to ensure that (i) health professionals involved in the care of pregnant women and (ii) pregnant women are informed about group B Streptococcus and (b) on effectiveness of tests used within the NHS to detect carriage of group B Streptococcus.
	tabling member constituency	Middlesbrough
	tabling member printed	Andy McDonald
	uin	8354
	answer	answer is ministerial correction date of answer 08/09/2015 answer text <p>The Royal College of Obstetricians and Gynaecologists (RCOG) has produced a Green-top guideline: Prevention of Early-Onset Neonatal Group B Streptococcal Disease. The Green-top guideline provides guidance for obstetricians, midwives and neonatologists on the prevention of early-onset neonatal group B streptococcal (GBS) disease. The first edition was published in 2003 and the second updated edition was published in 2012. An audit in partnership with the London School of Hygiene and Tropical Medicine and supported by the Royal College of Midwives was recently carried out by the RCOG. It examined current practice in preventing early- onset neonatal GBS disease by investigating the implementation of the RCOG Green-top guideline (2012 edition) and identified key areas for improvement. The first report was published on 5 March 2015 and found that the majority of obstetric units in the United Kingdom have written protocols to prevent early onset GBS disease in newborn babies. However, there is still variation in practice across units. The second report is due to be published later this year. Further information is available at:</p><p> </p><p><a href="https://www.rcog.org.uk/en/news/rcog-release-new-audit-into-gbs-finds-variation-in-practice-across-obstetric-units/" target="_blank">https://www.rcog.org.uk/en/news/rcog-release-new-audit-into-gbs-finds-variation-in-practice-across-obstetric-units/</a></p><p> </p><p> </p><p> </p><p>In addition the National Institute for Health and Care Excellence has published a clinical guideline which addresses early-onset GBS and other neonatal infections, ‘Antibiotics for early-onset neonatal infection: Antibiotics for the prevention and treatment of early-onset neonatal infection’ (August 2012).The clinical guideline is available at:</p><p> </p><p> </p><p> </p><p><strong> </strong><a href="http://www.nice.org.uk/guidance/cg149" target="_blank">http://www.nice.org.uk/guidance/cg149</a></p><p> </p><p> </p><p> </p><p>Information on GBS in pregnancy is publically available on the NHS Choices website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nhs.uk/conditions/pregnancy-and-baby/pages/pregnancy-infections.aspx" target="_blank">http://www.nhs.uk/conditions/pregnancy-and-baby/pages/pregnancy-infections.aspx</a>. The RCOG has also developed public information on early onset GBS:</p><p> </p><p> </p><p> </p><p><a href="https://www.rcog.org.uk/en/patients/patient-leaflets/group-b-streptococcus-gbs-infection-in-newborn-babies/" target="_blank">https://www.rcog.org.uk/en/patients/patient-leaflets/group-b-streptococcus-gbs-infection-in-newborn-babies/</a></p><p> </p><p>In June 2015, Public Health England (PHE) published the paper, ‘Enriched culture medium test for group B streptococcus infection: position paper’. The paper concluded that within current accepted clinical guidelines, there are no indications for testing women using enriched culture medium (ECM) methods. Therefore the ECM test has not been introduced into PHE laboratories. The position paper is available on the gov.uk website at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/publications/group-b-streptococcus-infection-enriched-culture-medium-test" target="_blank">https://www.gov.uk/government/publications/group-b-streptococcus-infection-enriched-culture-medium-test</a></p><p> </p><p> </p><p> </p><p>UK standards for microbiology investigations B58: Detection of carriage of Group B Streptococci, which was updated in June 2015, is publically available on the gov.uk website at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/publications/smi-b-58-processing-swabs-for-group-b-streptococcal-carriage" target="_blank">https://www.gov.uk/government/publications/smi-b-58-processing-swabs-for-group-b-streptococcal-carriage</a></p><p> </p> answering member constituency Ipswich answering member printed Ben Gummer question first answered 08/09/2015 15:48:06 answering member 3988 label Biography information for Ben Gummer
	tabling member	4269 label Biography information for Andy McDonald

392007

	registered interest
	date	21/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mental Health: Care Leavers
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what recent assessment they have made of mental health outcomes for young people who have been in local authority care.
	tabling member printed	Baroness Tyler of Enfield
	uin	HL1770
	answer	answer is ministerial correction date of answer 27/07/2015 answer text <p>No recent assessments have been made of the mental health outcomes amongst care leavers, or of their access to services. However, one of the themes of <em>Future in mind</em>, published in March 2015 was care for the most vulnerable, including looked after children and care leavers. Although care leavers may be adults, the report addressed the needs of those in transition to adult services and looked at how services could be improved for those with mental health conditions reaching the age of 18 when they generally transfer to adult services.</p><p> </p><p> </p><p> </p><p>The Government is currently considering how best to take forward proposals in <em>Future in mind </em>to deliver system-wide, sustainable transformation as well as the way in which the additional £1.25 billion made available in the 2015 Spring budget for children’s mental health over the course of the current Parliament will be used. However, decisions on how to allocate funding to best meet the needs of individual groups of children and young people will be made locally and reflected in local transformation plans.</p><p> </p><p> </p><p> </p><p>A copy of <em>Future in mind</em> is attached.</p><p> </p><p> </p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL1771 HL1772 question first answered 27/07/2015 14:16:07 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name Future in Mind.pdf title Future in Mind
	tabling member	4231 label Biography information for Baroness Tyler of Enfield

392009

	registered interest
	date	21/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mental Health Services: Children in Care
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what proportion of the additional £1.25 billion in funding for mental health services announced in the last Parliament will be spent on specialist services for children in care and young people who have been in local authority care.
	tabling member printed	Baroness Tyler of Enfield
	uin	HL1772
	answer	answer is ministerial correction date of answer 27/07/2015 answer text <p>No recent assessments have been made of the mental health outcomes amongst care leavers, or of their access to services. However, one of the themes of <em>Future in mind</em>, published in March 2015 was care for the most vulnerable, including looked after children and care leavers. Although care leavers may be adults, the report addressed the needs of those in transition to adult services and looked at how services could be improved for those with mental health conditions reaching the age of 18 when they generally transfer to adult services.</p><p> </p><p> </p><p> </p><p>The Government is currently considering how best to take forward proposals in <em>Future in mind </em>to deliver system-wide, sustainable transformation as well as the way in which the additional £1.25 billion made available in the 2015 Spring budget for children’s mental health over the course of the current Parliament will be used. However, decisions on how to allocate funding to best meet the needs of individual groups of children and young people will be made locally and reflected in local transformation plans.</p><p> </p><p> </p><p> </p><p>A copy of <em>Future in mind</em> is attached.</p><p> </p><p> </p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL1770 HL1771 question first answered 27/07/2015 14:16:07 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name Future in Mind.pdf title Future in Mind
	tabling member	4231 label Biography information for Baroness Tyler of Enfield

392010

	registered interest
	date	21/07/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mental Health Services: Children in Care
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what recent assessment they have made of access to mental health professionals with a specialism in attachment disorders, attention deficit hyperactivity disorder and autism spectrum disorder for young people over 18 years old who have been in local authority care.
	tabling member printed	Baroness Tyler of Enfield
	uin	HL1773
	answer	answer is ministerial correction date of answer 27/07/2015 answer text <p>No assessment has been made of access to mental health professionals with a specialism in attachment disorders, attention deficit hyperactivity disorder or autism spectrum disorder for young people over 18 years old who have been in local authority care.</p><p> </p><p><strong> </strong></p><p> </p> answering member printed Lord Prior of Brampton question first answered 27/07/2015 14:03:50 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	4231 label Biography information for Baroness Tyler of Enfield